Get the App

Back Stocks profile

Stock analysis tool for investors

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA | BSE:524715

₹1506.55 -13.60 (-0.89%) 1D

Pharmaceuticals & Biotechnology

Buy Sell
View detailed Technical chart

Open an Account with Bigul in 5 minutes

Performance

Today’s low

1500.00

Today’s High

1532.00

52W low

922.40

52W High

1638.80

Open Price

1531.00

Prev. Close

1570.2000

Volume

1933707.00

Value

2913226280.85

Fundamentals

Market Cap Cr

361471.80

Price to Earnings

40.60

Price to Book Value

6.10

Dividend Yield

0.80

PE to Growth

0.40

Op Revenue TTM Cr

47444.62

Net Profit TTM Cr

8906.27

Cash From Operating Activity Cr

4959.33

Return on Equity %

15.13

EMA & SMA

Bullish Moving Averages

5

Bearish Moving Averages

11

5Day EMA

1510.6

10Day EMA

1525.1

12Day EMA

1530.5

20Day EMA

1544.5

26Day EMA

1548.1

50Day EMA

1529.8

100Day EMA

1452.6

200Day EMA

1329.7

5Day SMA

1507.4

10Day SMA

1519.4

20Day SMA

1566.2

30Day SMA

1567.6

50Day SMA

1563.4

100Day SMA

1441.3

150Day SMA

1344.7

200Day SMA

1288.2

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

26 Apr, 2024

48.2

Week

65.6

Month

61.1

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

1512.87

PIVOT

First Resistance

1525.68

Second Resistance

1544.82

Third Resistance

1557.63

First Support

1493.73

Second Support

1480.92

Third Support

1461.78

Relative Strength Index

40.18

Money Flow Index

23.91

MACD

-17.6

MACD Signal

-7.52

Average True Range

34.94

Average Directional Index

29.15

Rate of Change (21)

-6.36

Rate of Change (125)

34.48

Commodity Channel Index

-80.3

Williams %R

-82.1

BETA

1 Month

1.31

3 Month

0.95

1 Year

0.35

3 Year

0.08

PRICE CHANGE ANALYSIS

↓ -1.07%

1 Week

Low

High

1477.7

1562.45

↓ -5.73%

1 Month

Low

High

1477.7

1638.85

↑ 10.1%

3 Months

Low

High

1355.2

1638.85

↑ 36.5%

6 Months

Low

High

1068.35

1638.85

↑ 55.11%

1 Year

Low

High

922.45

1638.85

Indicator Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Jun 2021 Graph
Total Qtr Revenue cr 5150.55 5202.75 4629.61 6068.52 4713.78 5327.00 4981.87 4307.29 4075.89 4427.42 3383.75
Operating Expenses Qtr 3714.75 3709.89 3517.31 3587.57 3646.37 3622.12 3483.22 3007.04 3114.27 3278.88 2694.46
Operating Profit Qtr 1359.00 1386.32 948.76 2360.65 999.38 1663.17 1449.66 999.84 656.39 864.27 631.49
EBIDT Qtr Cr 1365.99 1492.86 963.09 -456.84 1067.41 1704.88 1498.65 -354.71 961.62 1148.54 689.29
Depreciation Qtr 399.60 392.71 415.27 411.98 430.44 383.95 374.50 354.14 355.24 333.64 150.92
Net Profit Qtr 721.31 888.63 380.64 -1020.82 486.73 1213.01 1011.80 -1286.21 515.43 809.07 419.30
Basic EPS Qtr 3.00 3.70 1.60 -4.30 2.00 5.10 4.20 -5.40 2.10 3.40 1.75
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Total Revenue Annual 21091.17 16543.90 12953.43 14042.85 11574.65
Operating Expenses Annual Cr 14339.28 12678.46 9867.21 9820.28 8546.95
Operating Profit Annual 6472.86 2907.52 2936.00 2711.65 1756.26
Operating Profit Margin Annual % 30.69 17.57 22.67 19.31 15.17
Total Expenses Annual Cr 16412.33 14416.51 10711.00 10789.85 9640.82
EBIDT Annual Cr 6751.89 3865.44 3086.22 4222.57 3027.70
EBIDT Annual margin % 32.01 23.36 23.83 30.07 26.16
Depreciation 1600.87 1349.95 586.81 561.56 552.95
PAT Before ExtraOrdinary Items Annual Cr 1690.72 -99.99 2139.70 3211.14 816.60
Net Profit Annual 1690.72 -99.99 2139.70 3211.14 816.60
Basic EPS Annual 7.00 -0.40 8.92 13.40 3.40
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Total ShareHolders Funds Annual 23748.36 24587.95 25040.16 24396.22 22843.61
Minority Interest Liability Annual Cr - - - - -
Total Non Current Liabilities Annual Cr 8873.07 6071.70 5615.12 2810.37 1598.69
Total Current Liabilities Annual Cr 8366.06 10105.83 8343.55 11203.74 13271.83
Total Capital Plus Liabilities Annual Cr 40987.49 40765.48 38998.83 38410.33 37714.13
Fixed Assets Annual 9564.58 10541.42 6007.15 5825.35 5620.96
Total Non Current Assets Annual 24522.34 31061.73 26932.49 26469.21 26544.36
Total Current Assets Annual 16465.15 9703.75 12066.34 11941.12 11169.77
Total Assets Annual 40987.49 40765.48 38998.83 38410.33 37714.13
Contingent Liabilities plus Commitments Annual Cr 4309.60 3811.82 3564.25 3863.62 5549.82
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Cash from Operating Activity Annual 507.08 7636.36 1737.25 1305.85 1242.18
Cash from Investing Activity Annual -705.17 -2702.10 -601.80 1479.29 433.69
Cash from Financing Annual Activity 169.31 -4870.85 -1126.29 -2871.15 -1468.59
Net Cash Flow Annual -28.78 63.41 9.16 -86.01 207.28
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Book Value Per Share Annual 98.98 102.48 104.36 101.68 95.21
ROE Annual % 7.11 -0.40 8.54 13.16 3.57
ROCE Annual % 15.79 8.20 8.15 13.45 10.12
Total Debt to Total Equity Annual 0.32 0.20 0.26 0.24 0.26
EBDIT Annual Margin % 32.44 24.80 24.10 33.69 29.38
Indicator Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Jun 2021 Graph
Total Qtr Revenue cr 12630.90 12486.02 12145.28 11303.95 11414.85 11037.50 10763.90 9560.35 10295.57 9848.82 9871.26
Operating Expenses Qtr 8903.87 9013.03 8609.07 8128.54 8237.25 7995.73 7877.37 7106.39 7256.73 6995.99 6897.66
Operating Profit Qtr 3476.83 3179.38 3331.77 2802.13 3003.72 2956.55 2884.39 2340.37 2606.33 2629.94 2821.08
EBIDT Qtr Cr 3657.22 3472.99 3213.34 3003.96 3177.60 3041.77 2886.53 -1481.79 3038.84 2852.83 2342.53
Depreciation Qtr 622.14 632.82 651.32 671.53 659.95 609.95 588.00 556.47 553.68 530.37 503.22
Net Profit Qtr 2523.75 2375.51 2022.54 1984.47 2166.01 2262.22 2060.88 -2277.25 2058.80 2047.01 1404.04
Basic EPS Qtr 10.50 9.90 8.40 8.30 9.00 9.40 8.60 -9.50 8.60 8.50 6.00
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Total Revenue Annual 44520.20 39576.00 34333.66 33473.48 30091.40
Operating Expenses Annual Cr 32238.89 28256.77 25006.77 25847.74 22758.32
Operating Profit Annual 11646.79 10397.72 8491.37 6989.76 6307.59
Operating Profit Margin Annual % 26.16 26.27 24.73 20.88 20.96
Total Expenses Annual Cr 34940.32 30527.86 27228.15 28203.25 25066.82
EBIDT Annual Cr 12281.31 11319.23 9326.89 7625.74 7333.08
EBIDT Annual margin % 27.59 28.60 27.17 22.78 24.37
Depreciation 2529.43 2143.74 2079.95 2052.78 1753.25
PAT Before ExtraOrdinary Items Annual Cr 8560.84 3405.82 2284.68 4186.79 3209.32
Net Profit Annual 8473.58 3272.73 2903.82 3764.93 2665.42
Basic EPS Annual 35.30 13.60 12.10 15.70 11.10
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Total ShareHolders Funds Annual 55995.38 48011.22 46462.78 45264.45 41409.06
Minority Interest Liability Annual Cr 3320.09 3054.89 3017.05 3860.24 3313.54
Total Non Current Liabilities Annual Cr 1521.12 1533.21 2041.27 3421.34 2631.59
Total Current Liabilities Annual Cr 19907.00 17200.55 16145.63 15706.43 17339.62
Total Capital Plus Liabilities Annual Cr 80743.59 69799.87 67666.73 68252.46 64693.81
Fixed Assets Annual 20680.57 17197.09 16832.17 17585.79 17291.92
Total Non Current Assets Annual 40860.25 34784.89 37224.65 36598.30 33624.62
Total Current Assets Annual 39883.34 35014.98 30442.08 31654.16 31069.19
Total Assets Annual 80743.59 69799.87 67666.73 68252.46 64693.81
Contingent Liabilities plus Commitments Annual Cr 7903.07 6756.55 7057.73 7508.95 9316.47
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Cash from Operating Activity Annual 4959.33 8984.54 6170.37 6554.77 2196.45
Cash from Investing Activity Annual -7943.68 -5724.74 536.22 -2588.84 -681.25
Cash from Financing Annual Activity 2376.07 -5193.46 -5980.48 -5715.14 -2730.52
Net Cash Flow Annual -608.28 -1933.66 726.11 -1749.21 -1215.32
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Book Value Per Share Annual 247.22 212.84 206.23 204.75 186.40
ROE Annual % 15.13 6.81 6.24 8.31 6.43
ROCE Annual % 16.02 17.44 14.06 10.60 11.78
Total Debt to Total Equity Annual 0.11 0.02 0.07 0.17 0.24
EBDIT Annual Margin % 27.98 29.28 27.84 23.22 25.22
Name Holding Percent Holding Id Pledged % Locked %
Icici Prudential Value Discovery Fund 3.15 75037419 - -
Nps Trust- A/C Sbi Pension Fund Scheme - State Govt 1.17 75037424 - -
Government Pension Fund Global 1.04 75037429 - -
Name Holding Percent Holding Id Pledged % Locked %
Dilip. S. Shanghvi 9.6 75037402 0 0
Sudhir V. Valia 0.6 75037403 0 0
Shanghvi Finance Private Limited 40.3 75037409 0 0
Aditya Medisales Limited 1.67 75037410 0.02 0
Raksha S.Valia 1.2 75037411 92.58 0
Name Holding Percent Holding Id
Icici Prudential Value Discovery Fund 3.15 75037419
Sbi Nifty 50 Etf 2.27 75037420
Government Pension Fund Global 1.04 75037429
Life Insurance Corporation Of India 2.92 75037422
Nps Trust- A/C Sbi Pension Fund Scheme - State Govt 1.17 75037424
Name Holding Percent Holding Id
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Feb 09, 2024 8.5 INTERIM Feb 09, 2024 Equity Share
Jul 28, 2023 4 FINAL Jul 28, 2023 Equity Share
Feb 08, 2023 7.5 INTERIM Feb 08, 2023 Equity Share
Aug 19, 2022 3 FINAL Aug 22, 2022 Equity Share
Feb 09, 2022 7 INTERIM Feb 10, 2022 Equity Share
Aug 23, 2021 2 FINAL - Equity Share
Feb 09, 2021 5.5 INTERIM Feb 10, 2021 Equity Share
Aug 19, 2020 1 FINAL - Equity Share
Feb 17, 2020 3 INTERIM Feb 18, 2020 Equity Share
Aug 20, 2019 2.75 FINAL - Equity Share
Sep 17, 2018 2 FINAL - Equity Share
Sep 18, 2017 3.5 FINAL - Equity Share
Sep 08, 2016 1 FINAL - Equity Share
Oct 21, 2015 3 FINAL - Equity Share
Sep 11, 2014 1.5 FINAL - Equity Share
Sep 19, 2013 2.5 FINAL - Equity Share
Aug 14, 2012 4.25 INTERIM Aug 16, 2012 Equity Share
Sep 02, 2011 3.5 FINAL - Equity Share
Sep 09, 2010 13.75 FINAL - Equity Share
Aug 21, 2009 13.75 FINAL - Equity Share
Aug 25, 2008 10.5 FINAL - Equity Share
Mar 15, 2007 6.75 INTERIM Mar 16, 2007 Equity Share
Sep 06, 2006 5.5 FINAL - Equity Share
Sep 19, 2005 3.75 FINAL - Equity Share
Dec 10, 2004 3.25 INTERIM - Equity Share
Sep 24, 2003 5 FINAL - Equity Share
Oct 07, 2002 - FINAL - Equity Share
Aug 20, 2002 5 FINAL - Equity Share
Jul 17, 2001 - INTERIM Aug 01, 2001 Equity Share
Ex-Date Split Ratio Record Date
Nov 25, 2010 5:1 2010-11-26
Jan 13, 2003 10:5 2003-01-21
Ex-Date Purpose Notes
Jan 31, 2024 Quarterly Results & Interim Dividend -
Nov 01, 2023 Quarterly Results -
Aug 03, 2023 Quarterly Results -
May 26, 2023 Audited Results & Final Dividend -
Jan 31, 2023 Quarterly Results & Interim Dividend -
Nov 01, 2022 Quarterly Results -
Jul 29, 2022 Quarterly Results -
May 30, 2022 Audited Results & Final Dividend -
Jan 31, 2022 Quarterly Results & Interim Dividend -
Nov 02, 2021 Quarterly Results -
Jul 30, 2021 Quarterly Results -
May 27, 2021 Audited Results & Final Dividend -
Jan 29, 2021 Quarterly Results -
Nov 03, 2020 Quarterly Results -
Jul 31, 2020 Quarterly Results -
May 27, 2020 Audited Results & Final Dividend -
Mar 17, 2020 Buy Back of Shares -
Feb 06, 2020 Quarterly Results -
Nov 07, 2019 Quarterly Results -
Aug 13, 2019 Quarterly Results -
May 28, 2019 Audited Results & Dividend -
Feb 12, 2019 Quarterly Results -
Nov 13, 2018 Quarterly Results -
Aug 14, 2018 Quarterly Results -
May 25, 2018 Audited Results & Dividend -
Feb 14, 2018 Quarterly Results -
Nov 14, 2017 Quarterly Results -
May 26, 2017 Audited Results & Dividend -
Feb 14, 2017 Quarterly Results -
Nov 10, 2016 Quarterly Results & Others To consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited.
Aug 12, 2016 Quarterly Results -
Jun 23, 2016 Buy Back of Equity Shares -
May 30, 2016 Audited Results & Dividend -
Feb 12, 2016 Quarterly Results -
Nov 07, 2015 Quarterly Results -
Aug 11, 2015 Quarterly Results & Dividend Consideration of the revised audited annual accounts of the Co for the year ended 31/03/ 2015 after giving the effect to the Scheme of Amalgamation of SPGI into SPIL.
May 29, 2015 Audited Results & Amalgamation -
Feb 14, 2015 Quarterly Results -
Nov 13, 2014 Quarterly Results -
Aug 12, 2014 Revised Audited, Qtr Results & Dividend Consider the revised audited annual accounts of the Co. for the year ended March 31, 2014 after giving the effect to the Scheme of Arrangement and Reconstruction between between SPIL and SPGFZE.
May 29, 2014 Audited Results -
Feb 13, 2014 Quarterly Results -
Nov 13, 2013 Quarterly Results -
Aug 09, 2013 Quarterly Results -
May 28, 2013 Others -
Feb 08, 2013 Quarterly Results -
Nov 08, 2012 Quarterly Results -
Aug 10, 2012 Interim dividend & Others To consider the internal restructuring of the business of the Company with effect from March 31,2012 & to consider declaration of the interim dividend of Rs.4.25 per Share of Re.1 each.
May 29, 2012 Audited Results & Dividend -
Feb 13, 2012 Quarterly Results -
Nov 13, 2011 Quarterly Results -
Jul 28, 2011 Quarterly Results -
May 28, 2011 Audited Results & Dividend -
Jan 31, 2011 Quarterly Results -
Oct 30, 2010 Quarterly Results -
Sep 24, 2010 Stock split The Board has approved the proposal to sub-divide the nominal value of the Equity Shares of the Company from the nominal value of Rs. 5 each to the nominal value of Re. 1 each.
Jul 28, 2010 Quarterly Results -
May 24, 2010 Audited Results & Dividend -
Jan 29, 2010 Quarterly Results -
Oct 28, 2009 Quarterly Results -
Jul 29, 2009 Quarterly Results -
May 30, 2009 Audited Results & Dividend -
Jan 30, 2009 Quarterly Results -
Oct 25, 2008 Quarterly Results -
Jul 28, 2008 Quarterly Results -
May 30, 2008 Audited Results & Dividend -
Jan 30, 2008 Quarterly Results -
Oct 25, 2007 Quarterly Results & Others To consider payment of interim dividend @ 6% p.a. on outstanding 1,37,40,030 Preference Shares of Re 1/- each on prorata basis for the period from April 01, 2007 to November 01, 2007.
Jul 23, 2007 Quarterly Results -
May 18, 2007 Audited Results (Revised)
Mar 10, 2007 Interim Dividend -
Jan 29, 2007 Quarterly Results -
Oct 19, 2006 Quarterly Results -
Jul 26, 2006 Quarterly Results -
Jun 06, 2006 Accounts & Dividend Recommendation of payment of preference share dividend @ 6% p.a. on outstanding Preference Shares for the year ended March 31, 2006.
Feb 09, 2006 Demerger inter alia, to consider the proposal for demerger of the Company's Innovative Research & Development (including new drug delivery systems) undertaking to a new company.
Jan 30, 2006 Quarterly Results -
Oct 28, 2005 Quarterly Results -
Aug 18, 2005 Accounts & Dividend -
Jul 27, 2005 Quarterly Results -
Apr 27, 2005 Quarterly Results -
Apr 04, 2005 Acquisition of pharmaceutical business Decided to acquire pharmaceutical business of M J Pharmaceuticals Ltd including its manufacturing unit at Halol, Gujarat along with all its assets and liabilities pertaining to pharmaceutical business
Feb 08, 2005 Merger/Amalgamation To consider the proposal for merger / amalgamation of its wholly owned subsidiary companies (1) Bazley Finvest Pvt Ltd, (2) Dhaval Finvest Pvt Ltd and (3) Manish Finvest Pvt Ltd, with the Company.
Jan 21, 2005 Quarterly Results -
Nov 26, 2004 Interim Dividend & Others Issued US$ 275,000,000 Zero Coupon Foreign Currency Convertible Bonds (FCCB) due 2009 (subject to an increase of up to a further US$ 75,000,000 pursuant to the Option).
Oct 21, 2004 Quarterly Results -
Jul 31, 2004 Quarterly Results -
Apr 21, 2004 Dividend -
Apr 08, 2004 Others To consider the issue of convertible debentures/bonds/securities through global depository receipts.
Jan 28, 2004 Quarterly Results -
Oct 21, 2003 Quarterly Results (Revised)
Sep 30, 2003 Others To consider early closure of Buy Back programme of the Company through the Stock Exchange route before its normal validity period.
Jul 28, 2003 Quarterly Results -
May 03, 2003 Dividend & Accounts -
Jan 30, 2003 Quarterly Results -
Dec 20, 2002 Others Fix record date for stock split of shares.
Oct 28, 2002 Stock Split, Quarterly Results & Others from Rs.10/- each to Rs.5/- & & Buy Back of Shares
Jul 22, 2002 Quarterly Results -
Jun 28, 2002 Others To issue of Bonus Preference Shares to the equity shareholders
May 30, 2002 Accounts, Dividend & Others To take on record BIFR order regarding merger of M.J.Pharmaceuticals Ltd. after its restructuring and to fix record date for merger & Dividend & Accounts
Apr 26, 2002 Quarterly Results -
Mar 21, 2002 Interim Dividend (Cancelled)
Feb 15, 2002 Accounts To approve the annual accounts incorporationg PDCL merger for the year ended 31/03/2001.
Jan 22, 2002 Quarterly Results -
Nov 28, 2001 Others Interim dividend on Redeemable Cumulative Non-convertible Preference Shares issued by the Company.
Oct 19, 2001 Quarterly Results -
Jul 30, 2001 Interim Dividend & Quarterly Results -
Apr 19, 2001 Quarterly Results -
Mar 22, 2001 Merger Merger/Amalgamation of Sun Pharmaceutical Advanced Research Centre Ltd. with the Company, Interim Dividend on preference shares and Forfeiture of 500 partly paid equity shares
Feb 26, 2001 Others To appoint M/s. Price Waterhouse C.A., Mumbai as a valuers to determine exchange ratio for merger of Pradeep Drug Co. Ltd. and approve draft scheme of amalgamation/merger.
Feb 17, 2001 Others Amalgamation of Pradeep Drug Co. Ltd. with the Company
Jan 16, 2001 Quarterly Results -
Oct 18, 2000 Quarterly Results -
Jul 17, 2000 Quarterly Results -
Jun 06, 2000 Accounts -
Apr 28, 2000 Quarterly Results -
Apr 08, 2000 Merger/amalgamation -
Apr 01, 2000 Merger/Amalgamation -
Mar 18, 2000 2nd Interim Dividend -
Feb 01, 2000 Issue of bonus shares -
Jan 15, 2000 Quarterly Results -
Nov 06, 1999 Interim Dividend -
Oct 28, 1999 Quarterly Results, Accounts & Dividend -
Oct 27, 1999 Quarterly Results -
Jul 15, 1999 Quarterly Results -
Apr 29, 1999 Quarterly Results -
Dec 03, 1998 Others -
Nov 26, 1998 Amalgamation & Merger -
Nov 13, 1998 Pvt. Placements -
Oct 29, 1998 Quarterly Results -
Sep 25, 1998 Increase in Capital -
Jul 24, 1998 Quaterly Results -
Apr 18, 1998 Accounts & Dividend -
Feb 07, 1998 To consider allotment of equity shares -
Nov 29, 1997 Half Yearly Results -
Oct 21, 1997 Half Yearly Results. -
May 29, 1997 Amalgamation -
Apr 30, 1997 Accounts & Dividend. -
Ex-Date Bonus Ratio Record Date
Jul 29, 2013 1:1 2013-07-30
May 27, 2004 1:1 2004-05-29
Mar 06, 2000 2:1 2000-03-23
24 Apr 2024

Sun Pharma - Specialty' Way Of Driving Growth Prospects: Motilal Oswal

 Values Sun Pharma at 30 times 12 months forward earnings to arrive at a target price of Rs 1,870.
Bigul
23 Apr 2024

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliance Certificate Under Regulation 40(9) & (10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Submission of Compliance Certificate under Regulation 40(9) and (10) of SEBI LODR.
Bigul
23 Apr 2024

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation regarding Loss of Share Certificate
Bigul
19 Apr 2024

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order

 Intimation regarding regulatory order
18 Apr 2024

Sun Pharma-FDA: Regulatory Concerns At Dadra facility Can Dent Sentiment, Say Analysts

 Analysts say that the FDA action at the Dadra unit can push Sun Pharma's stock into a price-wise corrective phase.
Bigul
17 Apr 2024

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order

 Intimation regarding regulatory order
Bigul
15 Apr 2024

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliance Certificate Under Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Intimation regarding Compliance Certificate under Regulation 7 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
15 Apr 2024

Another regulatory blow for Sun Pharma after Dadra unit tagged 'OAI' by US FDA, stock down

 The official action indicated classification for the Dadra unit by FDA follows similar trouble at Sun Pharma's Halol and Mohali facilities recently, which hit generic sales
12 Apr 2024

Sun Pharma At Over Three-Week Low After FDA's Action On Dadra Plant

 The stock fell as much as 4.2% during the day on the NSE to the lowest since March 20.
Bigul
11 Apr 2024

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Dadra Facility Receives OAI Status From US FDA

 Intimation regarding Regulatory order
See all News

FAQs

The latest market price of Sun Pharmaceutical Industries Ltd. on NSE was Rs. 1506.55 as of today.

The opening share price of Sun Pharmaceutical Industries Ltd. was Rs. 1531.00 as of today.

The 52-week high share price of Sun Pharmaceutical Industries Ltd. was Rs. 1638.80.

The 52 week low share price of Sun Pharmaceutical Industries Ltd. was Rs. 922.40.

Sun Pharmaceutical Industries Ltd. has a market cap of Rs. 361471.80 crore as of today. Please refer to the Fundamentals section for further details.

The PE ratio of Sun Pharmaceutical Industries Ltd. is 0.40. Please refer to the Fundamentals section for further details.

The operating revenue for Sun Pharmaceutical Industries Ltd. in the last FY was Rs.  47444.62 crore. Please refer to the Financials section for further details.

The Net Profit for Sun Pharmaceutical Industries Ltd. in the last FY was Rs. 8906.27 crore. Please refer to the Financials section for further details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Sun Pharmaceutical Industries Ltd. was on 2024-02-09 for Rs. 8.5 per share. According to today’s share price, the dividend yield of Sun Pharmaceutical Industries Ltd. stands at 0.80. Please refer to the Corporate Actions section for further details.

The latest bonus issue declared by Sun Pharmaceutical Industries Ltd. was as of 2013-07-29. The bonus ratio declared in this issue was 1:1. Please refer to the Corporate Actions section for further details.

The latest split issue declared by Sun Pharmaceutical Industries Ltd. was as of 2003-01-13. The split ratio declared in this issue was 10:5. Please refer to the Corporate Actions section for further details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Sun Pharmaceutical Industries Ltd..

Close

Let's Open Free Demat Account